Windlas Biotech Limited
ICICI Prudential Mutual Fund sold 5,40,642 shares of Windlas Biotech for ₹43.12 crore at ₹797.55 apiece, decreasing its stake from 6.96% to 4.33% and crossing the 5% disclosure threshold.
A leading pharmaceutical contract development and manufacturing organization, Windlas Biotech specializes in producing solid and liquid dosage forms for domestic and international clients. The company provides comprehensive CDMO services including product discovery, development, and commercial manufacturing of generic and complex generic medications. Its vertically integrated operations, technical capabilities, and focus on quality manufacturing distinguish it within India's pharmaceutical sector.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.